SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

which would propel the drug into the top five biggest pharmaceutical sellers behind brands like AbbVie’s immunology blockbuster Humira (adalimumab), Merck & Co’s cancer immunotherapy Keytruda ...

Merck & Co/MSD’s three-drug antibiotic Recarbrio ... and Pfizer’s Amsparity – a biosimilar of AbbVie’s immunology blockbuster Humira (adalimumab).

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

Before 2009, Amgen's Vectibix (panitumumab), an inhibitor of epidermal growth factor receptor approved for colon cancer, and Humira (adalimumab ... J&J and in Europe by Merck of Whitehouse ...

Among TNF inhibitors, the highest persistence was observed with adalimumab. Differences in clinical response ... Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier and Vifor. Patient ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...